Characterisation of 3000 patient reported outcomes with predictive machine learning to develop a scientific platform to study fatigue in Inflammatory Bowel Disease
Hall, R.; Whelan, R. J.; Cartlidge, P. D.; Brownson, E. F.; Mowat, C.; Seenan, J. P.; MacDonald, J. C.; Campbell, I. A.; Ho, G.-T.; Chuah, C. S.
Show abstract
BackgroundFatigue is commonly identified by IBD patients as major issue that affects their wellbeing. This presentation, however, is complex, multifactorial and mired in clinical heterogeneity. Aims/MethodsWe prospectively captured patient reported outcomes (PROs) from 2 current IBD biomarker studies in Scotland with [~]100 clinical metadata points; and an international dataset (that includes non-IBD healthy controls) using CUCQ32, a validated IBD questionnaire to generate a contemporaneous dataset of fatigue and overall wellbeing (2021-2024) and utilized 6 different machine learning (ML) approaches to predict IBD-associated fatigue and patterns that may aid future stratification to human mechanistic and clinical studies. ResultsIn 2 970 responses from 2 290 participants, CUCQ32 were higher in active IBD vs. remission; and in remission, higher than in non-IBD controls (both p<0.0001). CUCQ32-specific fatigue score significantly correlated to all CUCQ32 components (p=2.9 x 10-28 to 3.2 x 10-147). During active IBD, patients had significantly more fatigue days compared to those in remission and non-IBD controls (medians 14 vs. 7 vs. 4 [out of 14 days]; both p<0.0001). We determine a threshold of [≥]10/14 days of fatigue as clinically relevant - Fatiguehigh. Overall, 72.8% (863/1185), 45.0% (408/906) and 13.7% (46/355) responses in active, remission and non-IBD controls were in Fatiguehigh. Using train-validate-test steps, we incorporated all available metadata to generate ML-models to predict Fatiguehigh. The 6 ML models performed similarly (all 6 models AUC of [~]0.70). SHapley Additive exPlanations (SHAP) analysis revealed that each algorithm places different importance on variables with seasonality, biologic drug levels, BMI and gender identified as factors. ML prediction of Fatiguehigh in patients in biochemical remission (CRP<5 mg/l and calprotectin <250g/g) was more challenging with AUC of 0.66-0.61. ConclusionWe provide a comprehensive patient involvement-ML-pathway to predict IBD-associated fatigue. Our data suggests a large hidden pathobiological component and current work is in progress to integrate deep molecular data and build a clinical-scientific ML model as a step towards better understanding of IBD-associated fatigue.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. 95%
- Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue is downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon 95%
- Antigen-driven expansion of public clonal T cell populations in inflammatory bowel diseases 95%
Similar papers in this journal
- Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic 95%
- Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool 94%
- Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease 93%
Similar papers in this journal
- Assessing Cellular and Transcriptional diversity of IIeal Mucosa amongst Treatment Naïve and Treated Crohn’s disease 95%
- Treatment-Specific Composition of Gut Microbiota Is Associated with Disease Remission in a Pediatric Crohn’s Disease Cohort 93%
- Epithelial cell biomarkers are predictive of response to biologic agents in Crohn's disease 93%
Similar papers in this journal
Similar papers in this journal
- The contribution of genetic risk and lifestyle factors in the development of adult-onset inflammatory bowel disease: a prospective cohort study 94%
- Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases 93%
- Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.